Results of the RIO-LIPIDS.

Rimonabant has been studied in more than 6,000 patients. Results of the RIO-LIPIDS written document showed that a one-year direction of overweight and obese patients with abnormal lipid levels with once daily rimonabant significantly reduced body weigth by an statistic of 6.9 kg in examination to a loss of 1.5 kg in the medicine abstraction. More importantly, it improved a chain of mountains of cardiometabolic risk factors that may contribute to type 2 diabetes and spirit disease. Results of a two-year care with rimonabant in the RIO-North Dry land discipline evidenced sustained effects on shank circuit, body artefact and cardiometabolic risk factors. Mechanism-based adverse effects associated with CB1 anatomical structure antagonists have not been reported. Results of the MUSICAL COMPOSITION trial run published in December 2006 showed that patients with type 2 diabetes not currently treated with anti-diabetic therapy experienced significant improvements in glucose criterion and unit as well as in HDL cholesterol and triglycerides. Importantly, about 57 % of the improvements in HbA1C were free-lance of the free weight loss achieved.